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ABSTRACT
Objectives The efﬁcacy and safety of sifalimumab
were assessed in a phase IIb, randomised, double-blind,
placebo-controlled study (NCT01283139) of adults with
moderate to severe active systemic lupus erythematosus
(SLE).
Methods 431 patients were randomised and received
monthly intravenous sifalimumab (200 mg, 600 mg or
1200 mg) or placebo in addition to standard-of-care
medications. Patients were stratiﬁed by disease activity,
interferon gene-signature test (high vs low based on the
expression of four genes) and geographical region. The
primary efﬁcacy end point was the percentage of
patients achieving an SLE responder index response at
week 52.
Results Compared with placebo, a greater percentage
of patients who received sifalimumab (all dosages) met
the primary end point (placebo: 45.4%; 200 mg:
58.3%; 600 mg: 56.5%; 1200 mg 59.8%). Other
improvements were seen in Cutaneous Lupus
Erythematosus Disease Area and Severity Index score
(200 mg and 1200 mg monthly), Physician’s Global
Assessment (600 mg and 1200 mg monthly), British
Isles Lupus Assessment Group-based Composite Lupus
Assessment (1200 mg monthly), 4-point reductions in
the SLE Disease Activity Index−2000 score and
reductions in counts of swollen joints and tender joints.
Serious adverse events occurred in 17.6% of patients on
placebo and 18.3% of patients on sifalimumab. Herpes
zoster infections were more frequent with sifalimumab
treatment.
Conclusions Sifalimumab is a promising treatment for
adults with SLE. Improvement was consistent across
various clinical end points, including global and organ-
speciﬁc measures of disease activity.
Trial registration number NCT01283139; Results.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic,
multisystem, autoimmune disease that predomin-
antly affects women of childbearing age. Its clinical
manifestations (eg, arthritis, rashes, alopecia, vascu-
litis, nephritis, serositis) lead to signiﬁcant morbid-
ity, reduced physical function, loss of employment,
impaired quality of life, high risk of permanent dis-
ability and shortened life span.1–3 Treatment of SLE
remains challenging because of the suboptimal efﬁ-
cacy of standard-of-care medications and the
serious adverse events associated with their use.4–6
Several studies, reviewed elsewhere,7–9 have sug-
gested a role for interferon-α (IFN-α) in the patho-
genesis of SLE.10–16 Distinct patterns of gene
expression induced by type I IFN11 17–19 are sub-
stantially upregulated in blood, skin biopsies and
synovial biopsies of patients with SLE compared
with healthy controls.20 This study aimed to inves-
tigate whether blocking the type I IFN pathway is
an effective approach for the treatment of SLE.
Sifalimumab is a fully human, immunoglobulin
G1 κ monoclonal antibody that binds to and neu-
tralises the majority of IFN-α subtypes. Clinical
trials of sifalimumab have established its safety
proﬁle and its suppression of IFN-α-induced genes,
and have suggested favourable effects on clinical
outcome measures.21 22 This phase IIb trial was
conducted to evaluate the efﬁcacy and safety of
three ﬁxed intravenous dosages of sifalimumab in
adults with moderate to severe active SLE with
inadequate responses to standard-of-care
treatments.
METHODS
Eligible patients were male or female, aged 18–
75 years, weighing ≥40 kg, fulﬁlling ≥4 of the 11
American College of Rheumatology (ACR) SLE
classiﬁcation criteria,23 24 and receiving stable
dosages of one or more of the following: oral pred-
nisone (≤20 mg/day, or equivalent); azathioprine
(≤150 mg/day); antimalarial treatment; mycophe-
nolate mofetil/mycophenolic acid (≤3.0 g/day); or
subcutaneous/oral methotrexate (≤20 mg/week).
Administration of stable dosages of non-steroidal
anti-inﬂammatory drugs was permitted. Prior to
enrolment, biological therapies had to be discontin-
ued for a sufﬁcient period to ensure they would no
longer have any pharmacodynamic and/or clinical
effect.
At screening, patients had to have positive ser-
ology for antinuclear (≥1:40), anti-Smith or
anti-double-stranded DNA (dsDNA) (≥100 IU/mL)
antibodies by the AtheNA Multi-Lyte ANA-II Plus
test system (Alere, Waltham, Massachusetts, USA).
Patients also had to meet the following disease
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activity criteria: SLE Disease Activity Index 2000
(SLEDAI-2K)25 score ≥6 with at least two points from a clinical
component (excluding SLE headache or organic brain syn-
drome), a British Isles Lupus Assessment Group
(BILAG)-200426 score of ≥1A or ≥2B organ system scores27
and a Physician’s Global Assessment (PGA) of disease activity
≥1 (scale: 0 (none) to 3 (severe)). Patients with active and severe
lupus nephritis or neuropsychiatric SLE were excluded from the
study. At randomisation, the overall SLEDAI-2K clinical compo-
nent score was required to be at or above the screening value.
Additional study exclusion criteria are provided in the online
supplementary material.
Study design
This study (NCT01283139), conducted at 107 sites in 20 coun-
tries, consisted of a 52-week, randomised, double-blind,
placebo-controlled, parallel-group treatment phase, followed by
a 22-week safety follow-up phase, and was conducted between
March 2011 and April 2014. All sites received ethics committee
or independent institutional review board approval before com-
mencement of the study.
Dosages of oral corticosteroids were required to remain stable
throughout the study, with the exception of limited, protocol-
deﬁned, oral corticosteroid burst (followed by a taper) for
increased SLE disease activity or protocol-permitted oral cor-
ticosteroid tapering (see online supplementary material).
The study was monitored by an independent data safety and
monitoring board, which included a rheumatologist and an
infectious disease expert. An independent external adjudication
group conﬁrmed SLE organ system involvement and disease
activity at screening, approved randomisation, and monitored
assessments and adherence throughout the trial.
This study was conducted in accordance with the principles
of the Declaration of Helsinki and the International Conference
on Harmonisation Guidance for Good Clinical Practice.
Independent ethics committee approval was obtained and all
patients provided written informed consent in accordance with
local requirements.
Randomisation and masking
Patients were randomised by an interactive voice and web man-
agement system (see online supplementary material) 1:1:1:1 to
receive intravenous placebo or sifalimumab 200 mg , 600 mg or
1200 mg on days 1, 15 and 29, and every 28 days thereafter.
Randomisation was stratiﬁed by IFN gene signature at screening,
SLEDAI-2K score (<10 or ≥10) at screening, and prespeciﬁed
geographical regions. Results of an IFN gene-signature test were
designated as high or low based on the expression of four
IFN-regulated genes (IFI27, IFI44, IFI44L, RSAD2).28
Geographical regions were based on a previous study22 and clin-
ical experience, which demonstrated greater standard-of-care
response rates for patients in central and South America, eastern
Europe and Asia (region 1), compared with patients in North
America, western Europe and South Africa (region 2).
Efﬁcacy and safety evaluations
The primary efﬁcacy end point was the percentage of patients
who achieved an SLE Responder Index (SRI(4)) response at
week 52. This was deﬁned as: a 4-point improvement in
SLEDAI-2K; no clinically signiﬁcant worsening (≥0.3) in PGA;
and no new BILAG-2004 ‘A’ (severe) or >1 new ‘B’ (moderate)
organ system scores.29
Secondary efﬁcacy measures, assessed at week 52, included
percentage of patients with decreased oral prednisone dosages
(≥10 mg/day, or equivalent, at baseline to ≤7.5 mg/day by week
52); ≥4-point reduction in Cutaneous Lupus Erythematosus
Disease Area and Severity Index (CLASI)30 31 for patients with
at least moderate skin involvement (CLASI ≥10); and >3-point
improvement in Functional Assessment of Chronic Illness
Therapy-Fatigue.32 Other prespeciﬁed efﬁcacy end points
included SLEDAI-2K25; modiﬁed SRI (mSRI) requiring
SLEDAI-2K reductions of 5–8 points; BILAG-based Combined
Lupus Assessment (BICLA)33; PGA; numbers of swollen and
tender joints; dsDNA; and C3 and C4 complement
concentrations.
Safety end points included reporting of adverse events
(Medical Dictionary for Regulatory Activities, V.17), laboratory
assessments and vital signs.
Statistical analysis
Analysis of the primary end point compared response rates at
week 52 between each sifalimumab group and placebo using a
logistic regression model with independent variables of treat-
ment group and randomisation stratiﬁcation factors. Patients
who withdrew from treatment had increased use of corticoster-
oids beyond that permitted (see online supplementary material),
or initiated or increased immunosuppressant dosage any time
after baseline were considered non-responders. Analyses were
performed in the modiﬁed intention-to-treat (mITT) population
(all randomised patients who received any investigational
product and had a baseline primary efﬁcacy measurement) and
an mITT subpopulation of patients with a high IFN gene signa-
ture. The study result was considered positive if the primary
end point was met in either of the two study populations.
The type-I error rate (α level) was controlled at approximately
0.10 (two-sided), within each of the populations for the
primary end point analysis, by performing a Cochran−Armitage
trend test of all treatment groups prior to performing pairwise
comparisons between each sifalimumab group and placebo. No
multiplicity adjustment for the two study populations or other
end points was applied.
One interim analysis was performed when 46% of primary
end point information was available. The two-sided α levels of
0.008 and 0.098 were allocated for the interim and ﬁnal ana-
lyses, respectively, using the O’Brien−Fleming-type Lan
−DeMets α spending function approach. Thus, a p value of
≤0.098 would be considered statistically signiﬁcant for the ﬁnal
analysis.
Exploratory post hoc analyses improved in number of affected
joints in a subset of patients with severe joint involvement at
baseline and assessment of clinical SLEDAI scores. These were
analysed using the aforementioned logistic regression model.
The target sample size of 400 (100 per group) was based on
providing 88% power at the 0.10 α level to detect at least 20%
absolute improvement in SRI(4) response rate at week 52 for
sifalimumab relative to placebo, assuming a 40% placebo
response rate.
The two-sided α level of 0.1 represents a 5% chance of
declaring a positive study when there is no treatment effect (risk
of proceeding with an ineffective drug). The power of 88%
represents a 12% chance of declaring a negative study when
there is a positive treatment effect (risk of discontinuing devel-
opment of a potentially efﬁcacious drug). This combination of
statistical risks was chosen to balance the continuation and dis-
continuation risks while maintaining a feasible phase IIb study.
All data analyses were conducted using the SAS System (SAS
Institute, Cary, North Carolina, USA).
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RESULTS
In total, 834 patients were screened, with 432 randomised to
treatment (108 placebo, 108 sifalimumab 200 mg, 109 sifalimu-
mab 600 mg, 107 sifalimumab 1200 mg, all monthly). One
patient in the 600 mg group had an entry criteria violation and
did not receive study treatment. Patient disposition is presented
in online supplementary ﬁgure S1. Demographics and baseline
disease characteristics are presented in table 1.
Table 1 Demographics and baseline clinical characteristics (mITT population)
Sifalimumab
Placebo (N=108) 200 mg* (N=108) 600 mg* (N=108) 1200 mg* (N=107)
Age (years), mean (SD) 38.4 (12.3) 39.9 (11.4) 40.0 (11.3) 39.4 (12.1)
Female, n (%) 101 (93.5) 103 (95.4) 97 (89.8) 97 (90.7)
Weight (kg), mean (SD) 66.2 (16.2) 68.5 (17.0) 66.7 (16.6) 67.6 (16.7)
Height (cm), mean (SD) 161.0 (8.2) 161.4 (9.4) 161.6 (9.4) 160.7 (9.2)
Race, n (%)
White 63 (58.3) 67 (62.0) 67 (62.0) 56 (52.3)
Asian 19 (17.6) 14 (13.0) 16 (14.8) 16 (15.0)
Black 7 (6.5) 8 (7.4) 7 (6.5) 11 (10.3)
American–Indian/Alaskan native 8 (7.4) 4 (3.7) 3 (2.8) 5 (4.7)
Other† 11 (10.2) 15 (13.9) 15 (13.9) 19 (17.8)
Ethnicity non-Hispanic, n (%) 68 (63.0) 72 (66.7) 68 (63.0) 63 (58.9)
Region, n (%)‡
1 74 (68.5) 75 (69.4) 74 (68.5) 73 (68.2)
2 34 (31.5) 33 (30.6) 34 (31.5) 34 (31.8)
Duration of SLE§ (months), mean (SD) 90.4 (74.9) 103.9 (84.9) 98.6 (82.6) 100.6 (94.9)
IFN-high, n (%) 88 (81.5) 87 (80.6) 88 (81.5) 87 (81.3)
Swollen joint count, mean (SD)¶ 6.3 (5.1) 6.6 (5.4) 6.8 (5.3) 6.4 (5.2)
Tender joint count, mean (SD)¶ 10.1 (7.5) 10.4 (7.7) 8.6 (6.8) 9.3 (7.2)
Low complement concentrations, n (%)
C3 47 (43.5) 45 (41.7) 46 (42.6) 47 (43.9)
C4 27 (25.0) 29 (26.9) 28 (25.9) 31 (29.0)
Antinuclear antibody positive, n (%)** 106 (99.1) 106 (99.1) 105 (97.2) 104 (99.0)
Anti-Smith antibody positive, n (%)†† 28 (25.9) 29 (26.9) 21 (19.6) 26 (24.8)
Anti-dsDNA positive, n (%)‡‡
Multiplex assay 30 (28.0) 30 (27.8) 27 (25.0) 29 (27.4)
Farr assay 82 (79.6) 85 (83.3) 87 (82.9) 80 (78.4)
Concomitant immunomodulatory medications, n (%)
Antimalarial 77 (71.3) 77 (71.3) 83 (76.9) 79 (73.8)
Azathioprine 28 (25.9) 31 (28.7) 31 (28.7) 21 (19.6)
Methotrexate 14 (13.0) 17 (15.7) 17 (15.7) 16 (15.0)
Mycophenolate 13 (12.0) 11 (10.2) 5 (4.6) 12 (11.2)
Corticosteroids 93 (86.1) 96 (88.9) 87 (80.6) 92 (86.0)
Dosage (mg/day)***, mean (SD) 11.1 (5.5) 10.9 (5.5) 10.8 (5.7) 11.6 (5.8)
SLEDAI-2K global score, mean (SD) 11.1 (4.1) 11.0 (4.0) 11.3 (4.6) 11.7 (4.7)
Score <10 40 (37.0) 46 (42.6) 39 (36.1) 42 (39.3)
Score ≥10 68 (63.0) 62 (57.4) 69 (63.9) 65 (60.7)
BILAG-2004 global score, mean (SD) 18.6 (4.9) 19.5 (5.2) 19.8 (6.4) 19.0 (5.6)
PGA, mean (SD) 1.83 (0.39) 1.81 (0.37) 1.73 (0.39) 1.77 (0.40)
CLASI activity score, mean (SD) 8.5 (8.5) 8.1 (7.4) 8.1 (7.2) 6.8 (6.2)
Multiplex assay: Placebo: N=107; 1200 mg: N=106; assessment at screening.
Farr assay: Placebo: N=103; 200 mg: N=102; 600 mg: N=105; 1200 mg: N=102; assessment on day 1.
*Days 1, 15 and 29, and then every 28 days thereafter.
†Other included one patient on placebo who identified herself as American–Indian, black and white.
‡Region 1 (high standard-of-care response): central America, South America, eastern Europe and Asia; Region 2 (low standard-of-care response): North America, western Europe and
South Africa.
§Duration from diagnosis to study entry.
¶A total of 28 joints were assessed.
**Placebo: N=107; 200 mg: N=107; 1200 mg: N=105; assessments at screening.
††600 mg: N=107; 1200 mg: N=105, assessments at screening.
‡‡The multiplex assay, AtheNA Multi-Lyte ANA-II Plus test system was used for screening and to calculate SLEDAI-2K scores throughout the study. The differences between the multiplex
and Farr assays were due to a low sensitivity cut-off point of the multiplex assay.37
***Prednisone dosage or equivalent.
BILAG-2004, British Isles Lupus Assessment Group; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; dsDNA, double-stranded DNA; IFN, interferon; PGA,
Physician’s Global Assessment; mITT, modified intention-to-treat; SLE, systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.
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Baseline characteristics were similar between groups, with the
following exceptions: disease duration was shorter for placebo
than for sifalimumab groups (90.4 vs 98.6–103.9 months) and
fewer patients in the 600 mg group were receiving mycopheno-
late (4.6% vs 10.2–12.0%). Baseline SLEDAI−2K and BILAG
−2004 scores were similar between the IFN-high and IFN-low
populations, and between patients from different regions.
However, there were differences between geographical regions
in several demographic and clinical characteristics (see online
supplementary table S1). Overall baseline disease activity mea-
sures were consistent with moderate to severe active SLE.
No neutralising antibodies to sifalimumab were found in any
patient over the course of the study.
At week 52, the Cochran–Armitage trend test of all treatment
groups showed that the number of patients achieving the
primary end point was greater for sifalimumab versus placebo
(p=0.053). Pairwise comparisons demonstrated that this effect
was consistent for each sifalimumab dosage (200 mg monthly:
58.3%, p=0.057; 600 mg monthly: 56.5%, p=0.094; 1200 mg
monthly: 59.8%, p=0.031) compared with placebo (45.4%)
(table 2) with improvements reaching a peak at week 24, after
which there was a plateau in the effect (ﬁgure 1). More patients
receiving sifalimumab versus placebo also achieved the prede-
ﬁned exploratory mSRI end points (table 2, ﬁgure 2).
The percentage of patients with improvements in CLASI
was greater for all sifalimumab dosages compared with placebo
(table 2); maximum improvement seen after 20–24 weeks
(ﬁgure 3). The percentage of patients receiving oral corticosteroids
≥10 mg/day at baseline who were tapered to ≤7.5 mg/day was low
in all groups (6–9%), although substantially more patients met pre-
deﬁned criteria for tapering in the sifalimumab 600 mg and
1200 mg monthly groups compared with placebo (table 2).
Table 2 Percentage of patients achieving efficacy end points at week 52 (mITT population)
Sifalimumab (%)
End point
Total number
of patients Placebo (%) 200 mg* p Value 600 mg* p Value 1200 mg* p Value
p Values
Cochran–Armitage test
Primary
SRI(4) 431 45.4 58.3 0.057 56.5 0.094 59.8 0.031 0.053
IFN-high 350 42.0 57.5 0.042 50.0 0.264 57.5 0.038 0.104
IFN-low 81 60.0 61.9 0.886 85.0 0.094 70.0 0.502 0.248
Region†
1 296 54.1 60.0 0.458 62.2 0.331 65.8 0.149 NC
2 135 26.5 54.5 0.019 44.1 0.102 47.1 0.073 NC
Secondary
CLASI‡ 127 48.6 72.7 0.044 57.6 0.498 73.1 0.049 NC
Fatigue§ 413 30.5 38.1 0.270 42.2 0.077 35.6 0.453 NC
Predefined
PGA ≤0.5 431 29.6 34.3 0.499 46.3 0.013 43.0 0.039 NC
mSRI(5) 430 39.3 50.9 0.071 43.5 0.458 54.2 0.024 NC
mSRI(6) 430 37.4 50.0 0.051 43.5 0.301 53.3 0.016 NC
mSRI(7) 388 24.5 40.8 0.008 43.0 0.004 44.4 0.002 NC
mSRI(8) 384 24.5 37.5 0.034 41.3 0.008 41.8 0.008 NC
IFN-high 312 20.3 35.1 0.027 35.5 0.027 41.3 0.004 NC
IFN-low 72 42.1 47.4 0.714 68.8 0.114 44.4 0.894 NC
BICLA¶ 429 36.1 45.4 0.177 46.7 0.114 48.1 0.072 NC
IFN-high 349 31.8 44.8 0.080 44.3 0.084 48.8 0.021 NC
IFN-low 80 55.0 47.6 0.624 57.9 0.891 45.0 0.526 NC
SLEDAI−2K4 431 45.4 58.3 0.057 58.3 0.050 61.7 0.014 NC
Meeting oral corticosteroid taper criteria** 368 34.4 35.4 0.914 48.3 0.065 50.0 0.026 NC
Flares†† 431 19.4 20.4 0.803 11.1 0.095 13.1 0.192 NC
Post hoc
50% joints‡‡ 155 36.8 53.7 0.086 57.9 0.031 60.5 0.024 NC
Clinical SLEDAI 431 48.6 58.3 0.144 59.3 0.097 63.6 0.023 NC
p Values in bold are, in the context of this study, statistically significant (p≤0.098).
*Days 1, 15 and 29, and then every 28 days thereafter.
†Region 1 (high standard-of-care response): central America, South America, eastern Europe and Asia; Region 2 (low standard-of-care response): North America, western Europe and
South Africa.
‡CLASI ≥10 at baseline with ≥4-point reduction (improvement) by week 52.
§>3-point improvement from baseline in FACIT-F score.
¶BICLA responder: reduction of baseline BILAG-2004 index ‘A’ to ‘B/C/D’ and ‘B’ to ‘C/D’, no BILAG-2004 index worsening in other organ systems (no new ‘A’ or ‘B’), increase in total
SLEDAI-2K of <1 and increase of PGA of <0.3.
**Percentage who met predefined criteria for oral corticosteroids taper: no increase in corticosteroids in the prior 3 months, SLEDAI-2K improvement ≥6 and PGA ≤0.5.
††Increase in disease activity resulting in an increased steroid use greater than baseline dosage.
‡‡≥50% decrease in both swollen and tender joint counts from baseline in patients with ≥8 swollen and ≥8 tender joints at baseline.
BICLA, BILAG-2004-based Combined Lupus Assessment; BILAG-2004, British Isles Lupus Assessment Group; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index;
FACIT-F, Functional Assessment of Chronic Illness Therapy−Fatigue; IFN, interferon; mITT, modified intention-to-treat; mSRI, modified SLE Responder Index; NC, not calculated; PGA,
Physician’s Global Assessment; SLEDAI-2K4, at least a 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000; Clinical SLEDAI, at least a 4-point reduction in
clinical components (no laboratory components) of Systemic Lupus Erythematosus Disease Activity; SRI(4), SLE Responder Index.
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Of the predeﬁned exploratory assessments, all sifalimumab
dosages resulted in greater percentages of patients achieving a
≥4-point reduction in SLEDAI-2K and having a positive BICLA
response compared with placebo. Trends towards greater
improvements with sifalimumab were noted for both the more
frequently (mucocutaneous, musculoskeletal) and less frequently
(haematological, renal, vascular) involved SLEDAI organ
systems (see online supplementary ﬁgure S2). Improvements in
PGA were also greater for the sifalimumab groups. Rates of
disease ﬂares, deﬁned as increased disease activity (new
BILAG-2004 ‘A’ or ‘B’ organ system score; SLEDAI-2K score
>3; or adverse events reﬂecting increased SLE disease activity)
resulting in an increase in oral corticosteroid dosages, were
lower for the 600 mg and 1200 mg monthly sifalimumab
groups compared with placebo. No speciﬁc differences between
the groups in changes from baseline or normalisation of C3/C4
complement concentrations (see online supplementary ﬁgure
S3) or anti-dsDNA concentrations (see online supplementary
ﬁgure S4) were observed. The percentage of patients achieving
the SRI(4) end point was not inﬂuenced by the type of
anti-dsDNA assay used (see online supplementary table S2).
Post hoc exploratory analyses demonstrated that in a subset of
patients with severe joint involvement (≥eight swollen and
≥eight tender joints) at baseline, there was a dosage-related
increase in the percentage of patients with ≥50% decrease in
affected joints, which was substantially greater for all dosages
Figure 1 Primary end point: patients achieving a SRI(4) at week 52
(mITT population). Treatment was administered on days 1, 15 and 29,
and then every 28 days thereafter. mITT, modiﬁed intention-to-treat;
SRI(4), systemic lupus erythematosus responder index.
Figure 2 Patients achieving an mSRI
response with 5-, 6-, 7-, or 8-point
decreases in SLEDAI-2K scores (mITT
population). *Primary end point.
Treatment was administered on days 1,
15 and 29, and then every 28 days
thereafter. mITT, modiﬁed
intention-to-treat; mSRI, modiﬁed
systemic lupus erythematosus
responder index; SLEDAI-2K, Systemic
Lupus Erythematosus Disease Activity
Index 2000.
Figure 3 Secondary end point. Panel A shows CLASI responder rate
(patients with a CLASI activity score greater ≥10 at baseline who
achieved a ≥4-point reduction) (mITT population). Panel B shows
examples from the 600 mg and 1200 mg groups of skin response
following sifalimumab treatment. (Full permission for use of these
images has been granted by patients.) Treatment was administered on
days 1, 15 and 29, and then every 28 days thereafter. CLASI,
Cutaneous Lupus Erythematosus Disease Area and Severity Index; mITT,
modiﬁed intention-to-treat; SLEDAI, Systemic Lupus Erythematosus
Disease Activity Index.
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versus placebo (table 2). There was also an apparent
dosage-related increase in the percentage of patients with clinic-
ally meaningful reductions in clinical SLEDAI response with
substantial improvements over placebo seen for the 600 mg and
1200 mg monthly dosages.
Subgroup analyses of SRI(4), mSRI(8) and BICLA by IFN test
status indicated that substantial improvements were observed for
IFN-high patients versus placebo (table 2). However, the small
number of IFN-low patients, comprising approximately 19% of
the study population, prevented a meaningful statistical com-
parison between patients based on IFN test status.
Differences were also observed in SRI(4) results in subgroup
analyses by geographical region, with higher response rates in
region 1 compared with region 2, although a greater distinction
between sifalimumab and placebo groups was seen in region 2
(see online supplementary ﬁgure S5). No differences between
the regions were seen in baseline SLEDAI-2K, PGA or
BILAG-2004 scores (data not shown) but, as previously men-
tioned, there were several differences in baseline demographic
and clinical characteristics (see online supplementary table S1).
The percentages of patients with at least one adverse event,
serious adverse event or adverse event leading to discontinu-
ation were similar across the groups (table 3). The most
common adverse events were worsening of SLE, urinary tract
infections, headaches, upper respiratory tract infections and
nasopharyngitis. There were ﬁve deaths during the double-blind
period: two in the placebo group (both septic shock); one in the
600 mg monthly group (cardiopulmonary arrest/sepsis) and two
in the 1200 mg group (stab wound, cardiopulmonary arrest/
transient ischaemic attack). There was one additional death
during the follow-up period (600 mg group; mitral valve
failure).
One patient (sifalimumab 1200 mg monthly) was diagnosed
with active tuberculosis and responded well to treatment. There
was one case of progressive multifocal leucoencephalopathy
(placebo) and one of viral encephalitis (sifalimumab 600 mg
monthly). Two grade 4 (life-threatening) infections were
reported with sifalimumab: bacterial enterocolitis (200 mg
monthly) and bacterial meningitis (1200 mg monthly). Both
resolved without sequelae following treatment. Serious infec-
tions were reported in eight (7.4%), nine (8.3%), seven (6.5%)
and eight (7.5%) patients on placebo, sifalimumab 200 mg,
600 mg and 1200 mg, respectively. There were no cases of sys-
temic fungal infection.
Herpes zoster infections were reported in 1 (0.9%) patient on
placebo compared with 19 (5.9%) patients treated with sifalimu-
mab, with the highest incidence in the sifalimumab 1200 mg
monthly group (table 3). All patients responded promptly to
antiviral treatment; one patient (sifalimumab 200 mg monthly)
experienced a recurrence of Herpes zoster during the study, and
one patient (sifalimumab 1200 mg monthly) discontinued
because of a Herpes zoster infection. In addition, one patient
(sifalimumab 1200 mg monthly) had ophthalmic Herpes zoster
noted at day 1, which was successfully treated.
One anaphylactic reaction (nasal congestion, chest discomfort,
tachycardia, facial ﬂushing, and swelling of the lips, tongue and
vulva in association with dyspnoea and bronchospasm) was
reported in a patient receiving placebo, which resolved within
Table 3 Adverse events (safety population)
Placebo (N=108)
Sifalimumab
200 mg* (N=108) 600 mg* (N=108) 1200 mg* (N=107) All dosages (N=323)
Patients with ≥1 event, n (%) 94 (87.0) 97 (89.8%) 97 (89.8%) 93 (86.9%) 287 (88.9%)
Serious adverse events, n (%) 19 (17.6) 16 (14.8%) 22 (20.4%) 21 (19.6%) 59 (18.3%)
Death, n (%) 2 (1.9) 0 (0.0%) 2 (1.9%) 2 (1.9%) 4 (1.2%)
Adverse events leading to discontinuation, n (%) 13 (12.0) 10 (9.3%) 12 (11.1%) 14 (13.1%) 36 (11.1%)
Grade 3 adverse events, n (%)† 17 (15.7) 16 (14.8%) 11 (10.2%) 18 (16.8%) 45 (13.9%)
Grade 4 adverse events, n (%)‡ 4 (3.7) 3 (2.8%) 3 (2.8%) 4 (3.7%) 10 (3.1%)
Adverse events of special interest, n (%)§ 10 (9.3) 14 (13.0%) 10 (9.3%) 18 (16.8%) 42 (13.0%)
Most common adverse events, n (%)¶
SLE (worsening) 37 (34.3) 36 (33.3%) 34 (31.5%) 27 (25.2%) 97 (30.0%)
Urinary tract infection 15 (13.9) 22 (20.4%) 17 (15.7%) 18 (16.8%) 57 (17.6%)
Headache 15 (13.9) 16 (14.8%) 15 (13.9%) 12 (11.2%) 43 (13.3%)
Upper respiratory tract infection 10 (9.3) 10 (9.3%) 17 (15.7%) 15 (14.0%) 42 (13.0%)
Nasopharyngitis 10 (9.3) 12 (11.1%) 13 (12.0%) 9 (8.4%) 34 (10.5%)
Bronchitis 9 (8.3) 12 (11.1%) 4 (3.7%) 15 (14.0%) 31 (9.6%)
Diarrhoea 8 (7.4) 7 (6.5%) 9 (8.3%) 5 (4.7%) 21 (6.5%)
Pharyngitis 4 (3.7) 3 (2.8%) 6 (5.6%) 12 (11.2%) 21 (6.5%)
Infusion-related reaction 6 (5.6) 8 (7.4%) 7 (6.5%) 5 (4.7%) 20 (6.2%)
Cough 7 (6.5) 7 (6.5%) 5 (4.6%) 6 (5.6%) 18 (5.6%)
Herpes zoster 1 (0.9) 5 (4.6%) 4 (3.7%) 10 (9.3%)** 19 (5.9%)**
Back pain 3 (2.8) 3 (2.8%) 8 (7.4%) 6 (5.6%) 17 (5.3% )
*Days 1, 15 and 29, and then every 28 days thereafter.
†An event that requires intensive therapeutic intervention. The event interrupts usual activities of daily living or significantly affects the clinical status of the patient.
‡An event or its immediate sequelae that is associated with an imminent risk of death or with physical or mental disabilities that affect or limit ability of patient to perform activities of
daily living.
§New or reactivated tuberculosis infection, Herpes zoster infection, malignancy, or reactions associated with infusion, hypersensitivity or anaphylaxis.
¶Adverse events reported by >5% of patients in the total (all dosages) sifalimumab group.
**Included one case of ophthalmic Herpes zoster, which began on day 1.
SLE, systemic lupus erythematosus.
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10 min following treatment with intravenous clorprenaline.
Hypersensitivity events occurred in two patients receiving
placebo, one of whom experienced two events, and three
patients on sifalimumab (200 mg, 1200 mg (2)). Of these, one
patient (placebo) discontinued treatment. Overall, there were
26 infusion-related reactions with a similar incidence in the
placebo (5.6%) and combined sifalimumab (6.2%) groups.
During the course of the study (including follow-up), no clin-
ically important shifts or changes were observed in haematology,
chemistry, urinalysis parameters, vital signs, lipid parameters or
ECG in any of the treatment groups.
DISCUSSION
This phase IIb study demonstrated greater efﬁcacy with IFN-α
pathway blockade than placebo in the treatment of patients with
moderate to severe active SLE and an inadequate response to
standard-of-care treatments. The broad-based improvement
measured in both SLE composite end points (SRI(4), BICLA)
and individual organ systems (CLASI, joint counts) supports
preclinical and clinical evidence that IFN-α plays an important
role in SLE pathogenesis.10 34–36 Although the 1200 mg dosage
provided the most consistent results, no clear sifalimumab
dosage effect was observed in the study. These potentially prom-
ising results are important in early drug development, but are
not deﬁnitive until prospectively replicated in larger studies with
a more stringent statistical signiﬁcance level (eg, α=0.05).
Assessment of SLE manifestations using SLEDAI-2K was less
sensitive in detecting improvements than more comprehensive
measures of individual organs. In particular, CLASI assessments
demonstrated greater sensitivity and rapidity in detecting skin
improvements compared with the SLEDAI-2K mucocutaneous
system assessments (ﬁgure 3), and the post hoc analysis of joint
improvements captured greater improvements compared with
the SLEDAI-2K musculoskeletal system assessments. Although
there was no requirement for patients to have a minimum
number of swollen/tender joints for inclusion in this study, the
positive ﬁndings from the exploratory analysis are encouraging,
given the high prevalence of arthritis among patients with lupus.
In the sifalimumab 600 mg group, there appeared to be a
slight reduction in CLASI responders, in the subset of patients
with baseline CLASI activity score ≥10, after week 28. As no
neutralising antibodies to sifalimumab were present in any
patient the reason for this decrease is not clear. Larger studies
would reduce the relatively high variabilities that are a conse-
quence of the small patient numbers in this subset (CLASI ≥10
at baseline) and provide a more precise estimate of effect. It
should be noted that despite a high placebo response rate in the
CLASI activity score, the response to sifalimumab was greater
than with placebo, with clear separation observed from
2 months. Sensitivity analysis (see online supplementary
table S3) at week 52 showed that, overall, 60.9% of patients
who received sifalimumab, compared with 40.0% who received
placebo, experienced a 50% improvement in CLASI for patients
with CLASI activity score ≥10 at baseline.
The greater distinction from placebo seen for the IFN-high
patients supports the hypothesis that the peripheral blood IFN
test status reﬂects systemic type I IFN activity. In contrast, for
IFN-low patients there was a smaller difference in response rates
between the placebo and the 200 mg or 1200 mg monthly sifali-
mumab groups. This is not due to a reduced response to sifali-
mumab, but to a greater placebo response rate; the reason for
which is unclear.
Although subgroup analysis of SRI(4) by geographical region
demonstrated greater response rates to both sifalimumab and
placebo in the predeﬁned high standard-of-care response
regions (region 1), the discrimination between the sifalimumab
and placebo groups was greater in the low standard-of-care
response regions (region 2). This was primarily due to a lower
response in the placebo group in region 2, and not to a lower
response to sifalimumab in region 1. The geographical disparity
was not attributable to differences in baseline SLEDAI-2K, PGA,
BILAG-2004 scores or baseline IFN gene signature which were
similar in both regions; however, it may be a reﬂection of vari-
ation in other baseline demographic or clinical characteristics
between the two regions (see online supplementary table S1).
Of note, in the placebo group a higher proportion of patients in
region 1 were taking corticosteroids compared with region 2,
whereas regional differences in use of these medications were
less pronounced in patients treated with sifalimumab. The
importance of this observation to explain the greater placebo
responses seen in region 1 remains to be determined.
Although the effect sizes observed in the overall population
were modest, the differences between the placebo and sifalimu-
mab treatment groups were clinically meaningful and similar to
those of other biological therapies. Under-representation of
patients from region 2 due to lower than anticipated enrolment
may have contributed to minimising the overall differences from
placebo. Further delineation of these regional anomalies deter-
mined from larger studies is warranted.
Adverse events occurred with similar frequencies in the sifali-
mumab and placebo groups, except for Herpes zoster infection,
which was more common with sifalimumab. This is consistent
with the mechanism of action of sifalimumab and safety results
reported from a previous study.22 Importantly, the clinical course
of Herpes zoster infections was uncomplicated in all cases. These
infections responded promptly to therapy, with only one recur-
rence among patients who continued receiving sifalimumab. As
modulation of the type I IFN pathway can potentially disrupt
mechanisms of viral defence and therefore, increase susceptibility
to viral infections or malignancies, additional, larger studies are
needed to fully characterise the safety of this treatment and to
deﬁne those at highest risk of complications.
In summary, this study demonstrated clinical efﬁcacy of inhi-
biting IFN-α with sifalimumab in SLE. The clinical effects of
sifalimumab are supported by improvements in both global and
organ-speciﬁc outcome measures, with an acceptable safety
proﬁle. Our observations demonstrate that blocking the type I
IFN pathway is a promising approach for the treatment of mod-
erate to severe active SLE.
Author afﬁliations
1Graham Hughes Lupus Research Laboratory, Division of Women’s Health, King’s
College London, The Rayne Institute, St Thomas’ Hospital, London, UK
2Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation,
Oklahoma City, Oklahoma, USA
3Lupus Research Institute, Philadelphia VA Medical Center, Philadelphia,
Pennsylvania, USA
4University of Pennsylvania, Philadelphia, Pennsylvania, USA
5Division of Rheumatology, Northwell Health, Great Neck, New York, USA
6Department of Rheumatology, UCSD School of Medicine, La Jolla, California, USA
7Clinical Development, Respiratory, Inﬂammation and Autoimmunity, MedImmune,
Gaithersburg, Maryland, USA
8Department of Biostatistics, MedImmune, Gaithersburg, Maryland, USA
Acknowledgements The authors thank the patients and investigators and their
site personnel who contributed to the study. The authors acknowledge Jennifer
Buynitzky, MS, MBA, of MedImmune and Michael A Nissen, ELS, of AstraZeneca for
their editorial contributions and facilitation of the development of the manuscript,
and Mark Hughes, PhD, of QXV Comms, an Ashﬁeld business, part of UDG
Healthcare, Macclesﬁeld, UK, who provided medical writing assistance.
Contributors Representatives of MedImmune conducted the data analyses. The ﬁrst
draft of this manuscript was written by WG, and all authors interpreted the data and
Khamashta M, et al. Ann Rheum Dis 2016;75:1909–1916. doi:10.1136/annrheumdis-2015-208562 1915
Clinical and epidemiological research
group.bmj.com on May 19, 2017 - Published by http://ard.bmj.com/Downloaded from 
participated in the preparation of the manuscript with support from professional
medical writers. All of the authors made the decision to submit the manuscript for
publication, and conﬁrm the veracity and completeness of the data and analyses, as
well as the ethical conduct and reporting of the study according to its trial protocol.
Funding The study was funded by MedImmune.
Competing interests MK received a grant for this study from MedImmune/
AstraZeneca; grants for other work from Bayer; and personal consultancy fees from
INOVA Diagnostics, MedImmune, GlaxoSmithKline and UCB. JTM reports personal
fees from MedImmune/AstraZeneca; and grants and personal fees from Genentech/
Roche outside of the submitted work. VPW received personal fees from
MedImmune/AstraZeneca, during the conduct of this study. RF, KK, GGI, JD, LW and
WG received personal fees from AstraZeneca/MedImmune. WG and GGI hold stocks
in AstraZeneca/MedImmune. JD has a patent pending. VPW is a named inventor
and holds a patent for the CLASI copyright owned by the University of Pennsylvania.
GGI, JD, LW and WG are employees of MedImmune.
Provenance and peer review Not commissioned; externally peer reviewed.
Ethics approval This study was conducted in accordance with the principles of the
Declaration of Helsinki and the International Conference on Harmonisation Guidance
for Good Clinical Practice. Independent ethics committee approval was obtained and
all patients provided written informed consent in accordance with local
requirements.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet
2014;384:1878–88.
2 Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus.
Arthritis Rheum 2006;54:2550–7.
3 Klein R, Moghadam-Kia S, Taylor L, et al. Quality of life in cutaneous lupus
erythematosus. JAAD 2011;64:849–58.
4 Petri M. Long-term outcomes in lupus. Am J Manag Care 2001;7:S480–5.
5 Doria A, Briani C. Lupus: improving long-term prognosis. Lupus 2008;17:166–70.
6 Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE.
Rheumatology (Oxford) 2012;51:1145–53.
7 Kirou KA, Gkrouzman E. Anti-interferon alpha treatment in SLE. Clin Immunol
2013;148:303–12.
8 Lauwerys BR, Ducreux J, Houssiau FA. Type I interferon blockade in systemic lupus
erythematosus: where do we stand? Rheumatology (Oxford) 2014;53:1369–76.
9 Herbst R, Liu Z, Jallal B, et al. Biomarkers for systemic lupus erythematosus. Int J
Rheum Dis 2012;15:433–44.
10 Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system
in systemic lupus erythematosus correlates with disease activity but not with
antiretroviral antibodies. Lupus 2000;9:664–71.
11 Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression
signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci
USA 2003;100:2610–15.
12 Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in
systemic lupus erythematosus blood. J Exp Med 2003;197:711–23.
13 Crow MK. Interferon-alpha: a new target for therapy in systemic lupus
erythematosus? Arthritis Rheum 2003;48:2396–401.
14 Kirou KA, Lee C, George S, et al. Coordinate overexpression of
interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum
2004;50:3958–67.
15 Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway
identiﬁes a subgroup of systemic lupus erythematosus patients with distinct
serologic features and active disease. Arthritis Rheum 2005;52:1491–503.
16 Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible
gene expression with disease activity and lupus nephritis in patients with systemic
lupus erythematosus. Arthritis Rheum 2006;54:2951–62.
17 Chiche L, Jourde-Chiche N, Whalen E, et al. Modular transcriptional repertoire
analyses of adults with systemic lupus erythematosus reveal distinct type I and type
II interferon signatures. Arthritis Rheum 2014;66:1583–95.
18 Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus
erythematosus. Lupus 2010;19:1012–19.
19 Welcher AA, Boedigheimer M, Kivitz AJ, et al. Blockade of interferon-γ normalizes
interferon-regulated gene expression and serum CXCL10 levels in patients with
systemic lupus erythematosus. Arthritis Rheum 2015;67:2713–22.
20 Yao Y, Higgs BW, Morehouse C, et al. Development of potential pharmacodynamic
and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic
lupus erythematosus. Hum Genomics Proteomics 2009;2009:Article ID 374312.
http://dx.doi.org/10.4061/2009/374312
21 Merrill JT, Wallace DJ, Petri M, et al. Safety proﬁle and clinical activity of
sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic
lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann
Rheum Dis 2011;70:1905–13.
22 Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-alpha
monoclonal antibody, in systemic lupus erythematosus: a phase I randomized,
controlled, dose-escalation study. Arthritis Rheum 2013;65:1011–21.
23 Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classiﬁcation of
systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
24 Hochberg MC. Updating the American College of Rheumatology revised criteria
for the classiﬁcation of systemic lupus erythematosus. Arthritis Rheum
1997;40:1725.
25 Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity
index 2000. J Rheumatol 2002;29:288–91.
26 Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial
validation of an updated version of the British Isles Lupus Assessment Group’s
disease activity index for patients with systemic lupus erythematosus. Rheumatology
(Oxford) 2005;44:902–6.
27 Yee CS, Cresswell L, Farewell V, et al. Numerical scoring for the BILAG-2004 index.
Rheumatology (Oxford) 2010;49:1665–9.
28 Yao Y, Higgs BW, Richman L, et al. Use of type I interferon-inducible mRNAs as
pharmacodynamic markers and potential diagnostic markers in trials with
sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthritis
Res Ther 2010;12(Suppl 1):S6.
29 Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus
erythematosus responder index. Arthritis Rheum 2009;61:1143–51.
30 Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus
Disease Area and Severity Index): an outcome instrument for cutaneous lupus
erythematosus. J Invest Dermatol 2005;125:889–94.
31 Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool
to measure disease severity and responsiveness to therapy in cutaneous lupus
erythematosus. Arch Dermatol 2011;147:203–8.
32 Smith E, Lai JS, Cella D. Building a measure of fatigue: the functional assessment of
Chronic Illness Therapy Fatigue Scale. PM R 2010;2:359–63.
33 Wallace DJ, Kalunian K, Petri MA, et al. Efﬁcacy and safety of epratuzumab in
patients with moderate/severe active systemic lupus erythematosus: results from
EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre
study. Ann Rheum Dis 2014;73:183–90.
34 Rönnblom L, Alm GV. Systemic lupus erythematosus and the type I interferon
system. Arthritis Res Ther 2003;5:68–75.
35 Dall’era MC, Cardarelli PM, Preston BT, et al. Type I interferon correlates with
serological and clinical manifestations of SLE. Ann Rheum Dis
2005;64:1692–7.
36 Abeler-Dörner L, Reiger CC, Berger B, et al. Interferon-α abrogates the suppressive
effect of apoptotic cells on dendritic cells in an in vitro model of systemic lupus
erythematosus pathogenesis. J Rheumatol 2013;40:1683–96.
37 Khamashta MA, Illei GG, Yoo S, et al. Decreased sensitivity of a commercial
anti-dsDNA assay in patients with moderately to severely active systemic lupus
erythematosus. Arthritis Rheum 2013;65:S669–70.
1916 Khamashta M, et al. Ann Rheum Dis 2016;75:1909–1916. doi:10.1136/annrheumdis-2015-208562
Clinical and epidemiological research
group.bmj.com on May 19, 2017 - Published by http://ard.bmj.com/Downloaded from 
double-blind, placebo-controlled study
lupus erythematosus: a randomised,
antibody, in moderate to severe systemic 
 monoclonalαSifalimumab, an anti-interferon-
Warren Greth
Kenneth Kalunian, Gabor G Illei, Jorn Drappa, Liangwei Wang and 
Munther Khamashta, Joan T Merrill, Victoria P Werth, Richard Furie,
doi: 10.1136/annrheumdis-2015-208562
2016
2016 75: 1909-1916 originally published online March 23,Ann Rheum Dis 
 http://ard.bmj.com/content/75/11/1909
Updated information and services can be found at: 
These include:
Material
Supplementary
 62.DC1
http://ard.bmj.com/content/suppl/2017/05/15/annrheumdis-2015-2085
Supplementary material can be found at: 
References
 #BIBLhttp://ard.bmj.com/content/75/11/1909
This article cites 36 articles, 11 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (571)Systemic lupus erythematosus
 (5144)Immunology (including allergy)
 (4253)Connective tissue disease
 (601)Open access
 (157)Editor's choice
 (83)ARD Lay summaries
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on May 19, 2017 - Published by http://ard.bmj.com/Downloaded from 
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on May 19, 2017 - Published by http://ard.bmj.com/Downloaded from 
